NEWARK, Calif., Nov. 5, 2013 /PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO) today reported financial results for the quarter ended September 30, 2013.
Third Quarter 2013 Financial and Operational Summary
"In the third quarter, we demonstrated significant revenue growth in both Gralise and Zipsor, and we are excited about the addition of Lazanda at the end of July," said Jim Schoeneck, President and Chief Executive Officer of Depomed. "Our recent sale of our non-core type 2 diabetes royalties, including Glumetza, to PDL BioPharma for $240.5 million gives the company significant flexibility to expand our business through acquisitions of marketed or late stage assets. With over $320 million in cash currently on our balance sheet, pending final tax considerations, and the strength of our core business in pain and neurology, we believe we are well positioned to become a leader in the central nervous system specialty pharmaceutical area."
Third Quarter 2013 Financial ResultsTotal revenues increased to $37.5 million for the third quarter of 2013, compared to $33.3 million for the third quarter of 2012 as indicated below:
Three Months Ended September 30,20132012Product sales:Gralise$
4,758Zipsor6,0224,926Lazanda444—Total product sales 16,2789,684Royalties:Glumetza US$
11,603Other844598Total royalty revenue15,42212,201License and other revenue:Glumetza$
1,388Janssen—10,005Mallinckrodt5,000—Other—4Total license and other revenue:5,76011,397Total revenues$
Selling general and administrative expense was $26.4 million for the third quarter of 2013 compared to $26.8 million for the third quarter of 2012. Third quarter 2013 expenses included two months of selling general and administrative expenses associated with Lazanda.Research and development expense was $1.3 million for the third quarter of 2013 compared to $5.3 million for the third quarter of 2012. The decrease is primarily related the Company ceasing all expenditure on Sefelsa™ during the first quarter of 2013 and the clinical trial expenses associated with our Phase 2 clinical trial of DM-1992 in third quarter 2012.
Net income for the third quarter of 2013 was $6.5 million or $0.11 per share, compared to a net loss of ($1.5) million or ($0.03) per share for the third quarter of 2012.
Cash and marketable securities were $85.4 million as of September 30, 2013 as compared to $74.2 million as of June 30, 2013. This does not include proceeds from the sale of type 2 diabetes milestones and royalties to PDL BioPharma, announced in October 2013.
Revised 2013 Guidance in Light of PDL Transaction Depomed is revising the financial outlook previously given for the full year of 2013 resulting from the sale of milestone and royalty interests in Depomed's type 2 diabetes portfolio to PDL Biopharma in October 2013.
Conference CallDepomed will host a conference call today, Tuesday, November 5 beginning at 5:00 p.m. EST (2:00 p.m. PST) to discuss its results. Participants can access the call by dialing 877-317-6789 (United States) or 412-317-6789 (international). The conference call will also be available via a live webcast on the investor relations section of Depomed's website at http://www.depomed.com. Access the website 15 minutes prior to the start of the call to download and install any necessary audio software. An archived webcast replay will be available on the Company's website for three months.
About DepomedDepomed, Inc. is a specialty pharmaceutical company with four approved and marketed products. Gralise® (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia (PHN). Zipsor® (diclofenac potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug (NSAID) indicated for relief of mild to moderate acute pain in adults.
Lazanda® (fentanyl) Nasal Spray is an intranasal fentanyl drug used to manage breakthrough pain in adults (18 years of age or older) who are already routinely taking other opioid pain medicines around-the-clock for cancer pain. Glumetza® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and is commercialized by Santarus, Inc. in the United States. Gralise and Glumetza and other product candidates are formulated with Depomed's proven, proprietary Acuform® drug delivery technology, which is designed to improve existing oral medications, allowing for extended release of medications to the upper gastrointestinal tract when dosed with food. Additional information about Depomed may be found on its website, www.depomed.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995. The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties including, but not limited to, those related to the commercialization of Gralise, Zipsor and Lazanda and other risks detailed in the company's Securities and Exchange Commission filings, including the company's Annual Report on Form 10-K for the year ended December 31, 2012 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2013. The inclusion of forward-looking statements should not be regarded as a representation that any of the company's plans or objectives will be achieved. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
August J. Moretti
Canale Communications for Depomed
firstname.lastname@example.orgDEPOMED, INC.CONDENSED STATEMENTS OF OPERATIONS (in thousands, except share and per share amounts)Three Months Ended September 30,Nine Months Ended September 30,2013201220132012Revenues:Product sales $
14,994Royalties 15,42212,20144,59931,199License and other revenue 5,76011,3979,48418,033Total revenues 37,46033,28293,59664,226Costs and expenses:Cost of sales 1,7511,7634,9233,723Research and development expense 1,3395,2706,04912,277Selling, general and administrative expense26,37426,83277,70573,625Amortization of intangible assets1,1589583,0821,063Total costs and expenses 30,62234,82391,75990,688Income (loss) from operations 6,838(1,541)1,837(26,462)Other income (expense)(258)57(298)405Benefit from (provision for) income taxes (66)(11)(27)(20)Net income (loss)$
(26,077)Basic net income (loss) per common share $
(0.47)Diluted net income (loss) per common share $
(0.47)Shares used in computing basic net income (loss) per common share 56,818,88356,039,18656,615,35955,794,357Shares used in computing diluted net income (loss) per common share 57,661,21256,039,18657,316,83055,794,357 DEPOMED, INC.CONDENSED BALANCE SHEETS(in thousands)September 30,December 31,20132012(Unaudited)(1)Cash, cash equivalents and marketable securities
77,892Accounts receivable8,3123,614Receivables from collaborative partners7,76910,078Inventories7,8229,587Property and equipment, net8,3828,237Intangible assets, net32,62625,078Prepaid and other assets6,4717,167Total Assets
141,653Accounts payable and accrued liabilities
32,578Deferred license revenue16,41718,789Other liabilities8,0395,008Contingent consideration liability9,7871,342Shareholders' equity92,21383,936Total liabilities and shareholders' equity
(1) Derived from the audited financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2012.
|SOURCE Depomed, Inc.|
Copyright©2012 PR Newswire.
All rights reserved